866-997-4948(US-Canada Toll Free)

Uveitis - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Diseases & Conditions

No. of Pages : 186 Pages

Uveitis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H1 2017, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 8, 5, 2, 29, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Uveitis - Overview 8
Uveitis - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 19
Uveitis - Therapeutics Assessment 20
Assessment by Target 20
Assessment by Mechanism of Action 23
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Uveitis - Companies Involved in Therapeutics Development 30
2-BBB Medicines BV 30
Aciont Inc 30
Aldeyra Therapeutics Inc 31
Apitope International NV 31
Astellas Pharma Inc 32
Bionomics Ltd 32
Bristol-Myers Squibb Company 33
Can-Fite BioPharma Ltd 33
Clearside BioMedical Inc 34
Coherus BioSciences Inc 34
Elasmogen Ltd 35
Endocyte Inc 35
Enzo Biochem Inc 36
EyeGate Pharmaceuticals Inc 36
Eyevensys SAS 37
F. Hoffmann-La Roche Ltd 37
HanAll Biopharma Co Ltd 38
Icon Bioscience Inc 38
Idera Pharmaceuticals Inc 39
InnoMedica Holding AG 39
KPI Therapeutics Inc 40
Midatech Pharma Plc 40
Mitotech SA 41
Nemus Bioscience Inc 41
Neuroptis Biotech 42
Novartis AG 42
Oculis ehf 43
OncoNOx ApS 43
Orchid Pharma Ltd 44
OSE Immunotherapeutics 44
Palatin Technologies Inc 45
Panacea Biotec Ltd 45
Panoptes Pharma GesmbH 46
Pfizer Inc 46
pSivida Corp 47
Re-Pharm Ltd 47
Regeneron Pharmaceuticals Inc 48
Sandoz International GmbH 48
Santen Pharmaceutical Co Ltd 49
SynDevRx Inc 49
TxCell SA 50
Uveitis - Drug Profiles 51
2B-3201 - Drug Profile 51
abatacept - Drug Profile 53
adalimumab biosimilar - Drug Profile 60
adalimumab biosimilar - Drug Profile 61
adalimumab biosimilar - Drug Profile 63
adalimumab biosimilar - Drug Profile 64
ADX-102 - Drug Profile 65
Antisense Oligonucleotide to Inhibit NLRP3 for Uveitis, Cystitis and Inflammatory Disorders - Drug Profile 70
Antisense RNAi Oligonucleotide to Inhibit ProRenin Receptor for Uveitis and Diabetic Retinopathy - Drug Profile 71
ANV-103 - Drug Profile 72
ATXUV-1 - Drug Profile 73
B27-PD - Drug Profile 74
BNC-164 - Drug Profile 75
celecoxib - Drug Profile 76
Col-Treg - Drug Profile 79
CVX-001 - Drug Profile 81
cyclosporine SR - Drug Profile 82
dalazatide - Drug Profile 83
dexamethasone acetate - Drug Profile 88
dexamethasone acetate - Drug Profile 93
dexamethasone acetate - Drug Profile 95
dexamethasone sodium phosphate - Drug Profile 96
Drug for Chronic Uveitis - Drug Profile 98
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 99
EBI-031 - Drug Profile 100
EC-1669 - Drug Profile 101
ELN-21 - Drug Profile 102
ELN-22 - Drug Profile 103
EYS-606 - Drug Profile 104
fluocinolone acetonide SR - Drug Profile 105
FR-104 - Drug Profile 113
Gene Therapy for Dry Age-Related Macular Degeneration and Uveitis - Drug Profile 116
HL-036 - Drug Profile 117
HO-10 - Drug Profile 118
IVMED-10 - Drug Profile 119
IVMED-20 - Drug Profile 120
KPI-190 - Drug Profile 121
latanoprost SR - Drug Profile 122
LME-636 - Drug Profile 123
lodamin - Drug Profile 124
methotrexate - Drug Profile 125
NB-2222 - Drug Profile 126
NOP-3 - Drug Profile 127
OX-1001 - Drug Profile 128
piclidenoson - Drug Profile 129
PL-8177 - Drug Profile 138
plastoquinone decyl triphenylphosphonium bromide - Drug Profile 139
PP-001 - Drug Profile 141
PPL-003 - Drug Profile 143
RP-0217 - Drug Profile 145
sarilumab - Drug Profile 146
sirolimus - Drug Profile 153
Small Molecule to Inhibit PDE4B and TNF Alpha for Asthma, COPD and Uveitis - Drug Profile 156
Small Molecules for Posterior Uveitis - Drug Profile 157
Small Molecules to Inhibit 5-Lipoxygenase for Uveitis - Drug Profile 158
Small Molecules to Inhibit TYK2 for Psoriasis and Uveitis - Drug Profile 159
Stem Cell Therapy for Autoimmune Diseases - Drug Profile 160
tesidolumab - Drug Profile 162
triamcinolone acetonide - Drug Profile 164
Uveitis - Dormant Projects 170
Uveitis - Discontinued Products 173
Uveitis - Product Development Milestones 174
Featured News & Press Releases 174
Appendix 181
Methodology 181
Coverage 181
Secondary Research 181
Primary Research 181
Expert Panel Validation 181
Contact Us 181
Disclaimer 182

List of Tables
Number of Products under Development for Uveitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Uveitis - Pipeline by 2-BBB Medicines BV, H1 2017
Uveitis - Pipeline by Aciont Inc, H1 2017
Uveitis - Pipeline by Aldeyra Therapeutics Inc, H1 2017
Uveitis - Pipeline by Apitope International NV, H1 2017
Uveitis - Pipeline by Astellas Pharma Inc, H1 2017
Uveitis - Pipeline by Bionomics Ltd, H1 2017
Uveitis - Pipeline by Bristol-Myers Squibb Company, H1 2017
Uveitis - Pipeline by Can-Fite BioPharma Ltd, H1 2017
Uveitis - Pipeline by Clearside BioMedical Inc, H1 2017
Uveitis - Pipeline by Coherus BioSciences Inc, H1 2017
Uveitis - Pipeline by Elasmogen Ltd, H1 2017
Uveitis - Pipeline by Endocyte Inc, H1 2017
Uveitis - Pipeline by Enzo Biochem Inc, H1 2017
Uveitis - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017
Uveitis - Pipeline by Eyevensys SAS, H1 2017
Uveitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Uveitis - Pipeline by HanAll Biopharma Co Ltd, H1 2017
Uveitis - Pipeline by Icon Bioscience Inc, H1 2017
Uveitis - Pipeline by Idera Pharmaceuticals Inc, H1 2017
Uveitis - Pipeline by InnoMedica Holding AG, H1 2017
Uveitis - Pipeline by KPI Therapeutics Inc, H1 2017
Uveitis - Pipeline by Midatech Pharma Plc, H1 2017
Uveitis - Pipeline by Mitotech SA, H1 2017
Uveitis - Pipeline by Nemus Bioscience Inc, H1 2017
Uveitis - Pipeline by Neuroptis Biotech, H1 2017
Uveitis - Pipeline by Novartis AG, H1 2017
Uveitis - Pipeline by Oculis ehf, H1 2017
Uveitis - Pipeline by OncoNOx ApS, H1 2017
Uveitis - Pipeline by Orchid Pharma Ltd, H1 2017
Uveitis - Pipeline by OSE Immunotherapeutics, H1 2017
Uveitis - Pipeline by Palatin Technologies Inc, H1 2017
Uveitis - Pipeline by Panacea Biotec Ltd, H1 2017
Uveitis - Pipeline by Panoptes Pharma GesmbH, H1 2017
Uveitis - Pipeline by Pfizer Inc, H1 2017
Uveitis - Pipeline by pSivida Corp, H1 2017
Uveitis - Pipeline by Re-Pharm Ltd, H1 2017
Uveitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Uveitis - Pipeline by Sandoz International GmbH, H1 2017
Uveitis - Pipeline by Santen Pharmaceutical Co Ltd, H1 2017
Uveitis - Pipeline by SynDevRx Inc, H1 2017
Uveitis - Pipeline by TxCell SA, H1 2017
Uveitis - Dormant Projects, H1 2017
Uveitis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Uveitis - Dormant Projects, H1 2017 (Contd..2), H1 2017
Uveitis - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Uveitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *